TP53 and neoplasm: In this sense, previous studies showed that both SIRT1 and SIRT6 limit tumor onset and development in p53 deficient mouse models (Wang et al., 2008; Ghosh et al., 2018), uncovering the important tumor suppressor functions of these Sirtuins.